KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Deferred Taxes (2018 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed Deferred Taxes for 8 consecutive years, with -$1.1 million as the latest value for Q4 2025.

  • Quarterly Deferred Taxes rose 87.06% to -$1.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$3.2 million through Dec 2025, up 63.92% year-over-year, with the annual reading at -$3.2 million for FY2025, 63.92% up from the prior year.
  • Deferred Taxes for Q4 2025 was -$1.1 million at Xenon Pharmaceuticals, down from -$701000.0 in the prior quarter.
  • The five-year high for Deferred Taxes was $403000.0 in Q1 2024, with the low at -$8.6 million in Q4 2024.
  • Average Deferred Taxes over 5 years is -$617000.0, with a median of -$185000.0 recorded in 2023.
  • The sharpest move saw Deferred Taxes skyrocketed 2766.67% in 2022, then plummeted 4206.0% in 2024.
  • Over 5 years, Deferred Taxes stood at $346000.0 in 2021, then crashed by 98.55% to $5000.0 in 2022, then crashed by 4100.0% to -$200000.0 in 2023, then tumbled by 4206.0% to -$8.6 million in 2024, then surged by 87.06% to -$1.1 million in 2025.
  • According to Business Quant data, Deferred Taxes over the past three periods came in at -$1.1 million, -$701000.0, and -$170000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.